NCT06353386 2026-03-13
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
Clinical Trials
10 trialsNCT06691984 2026-03-06
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Amgen
Phase 3 Recruiting
NCT06632977 2026-03-04
PREDICT
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT05818683 2026-02-13
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06470243 2026-01-22
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
SWOG Cancer Research Network
Phase 3 Recruiting
NCT03258320 2026-01-12
A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients
Shanghai Jiao Tong University School of Medicine
Phase 2/3 Recruiting
NCT06738303 2025-08-27
CATCH-177
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT03903835 2025-04-09
ProBio
Karolinska Institutet
Phase 3 Recruiting
NCT05762536 2024-06-27
DAROTAXEL
Erasmus Medical Center
Phase 2 Recruiting
NCT05563558 2024-06-11
PEAPOD_FOS
Fundacion Oncosur
Phase 2 Recruiting